Our study provides a convincing reference for future researches on the advent of potential targeted drugs and will allow clinicians to stratify SCLC patients into ASCL1 high and low groups according to expression level, which is of crucial importance in selecting potential patients that may benefit from treatment in the future. Here, ASCL1 is linked to small cell lung carcinoma.